Preparation of  188 Re-Labetalol as a β 1 -Adrenoceptor for Use in Nuclear Medicine

F. A. Marzook; H. E. Ramadan; H. M. Talaat

doi:10.1134/S1066362219020188

Preparation of ¹⁸⁸Re-Labetalol as a β₁-Adrenoceptor for Use in Nuclear Medicine

作者: Marzook F.A.¹, Ramadan H.E.², Talaat H.M.¹
隶属关系:
1. Labeled Compounds Department, Hot Laboratories Center
2. Radioactive Isotopes and Generator Department, Hot Laboratories Center
期: 卷 61, 编号 2 (2019)
页面: 238-243
栏目: Article
URL: https://ogarev-online.ru/1066-3622/article/view/225110
DOI: https://doi.org/10.1134/S1066362219020188
ID: 225110

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
补充文件
统计

详细

Labetalol was labeled with ¹⁸⁸Re. The reaction conditions (amounts of stannous chloride and substrate, pH, time) were optimized, and the radiochemical yield as high as 95 ± 0.4% was reached. Biodistribution in mice was studied. ¹⁸⁸Re-Labetalol showed excellent initial heart uptake and good retention. The heart/liver ratios were 5.16, 2.70, and 2.15 at 30, 60, and 120 min post injection, respectively.